PreppinPeppers › Facts › Lab article
ACE-031: Reference Overview and Reconstitution Notes
TL;DR
ACE-031 (ramatercept) is an experimental protein being studied for its effects on muscle mass. It is for research only and has not been approved by the FDA.
Agent view of https://www.preppinpeppers.com/blogs/the-lab/ace-031: the machine-readable facts of this Lab article. People see the full page at the same URL. Facts page: https://www.preppinpeppers.com/facts/ace-031.
Facts Index
| Fact ID | Category | Entity | Attribute | Value | Source |
|---|---|---|---|---|---|
| ace-031:title | identity | ACE-031: Reference Overview and Reconstitution Notes | title | ACE-031: Reference Overview and Reconstitution Notes | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:published | identity | ACE-031: Reference Overview and Reconstitution Notes | published | 2026-08-15 | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:last-reviewed | identity | ACE-031: Reference Overview and Reconstitution Notes | last reviewed | 2026-10-19 | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:author | identity | ACE-031: Reference Overview and Reconstitution Notes | author | Preppin' Peppers Editorial Team | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:topics | identity | ACE-031: Reference Overview and Reconstitution Notes | topics | Investigational, research | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:summary | content | ACE-031: Reference Overview and Reconstitution Notes | summary | ACE-031 (ramatercept) is an experimental protein being studied for its effects on muscle mass. It is for research only and has not been approved by the FDA. | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:section-1 | content | ACE-031: Reference Overview and Reconstitution Notes | section | What it is | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:section-2 | content | ACE-031: Reference Overview and Reconstitution Notes | section | ACE-031 | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:section-3 | content | ACE-031: Reference Overview and Reconstitution Notes | section | What it is | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:section-4 | content | ACE-031: Reference Overview and Reconstitution Notes | section | Research context and categorization | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:section-5 | content | ACE-031: Reference Overview and Reconstitution Notes | section | Status | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:section-6 | content | ACE-031: Reference Overview and Reconstitution Notes | section | Reconstitution notes (general) | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:section-7 | content | ACE-031: Reference Overview and Reconstitution Notes | section | Dilution and handling notes (compound-specific) | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:section-8 | content | ACE-031: Reference Overview and Reconstitution Notes | section | Handling and storage | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:section-9 | content | ACE-031: Reference Overview and Reconstitution Notes | section | Related reading | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:section-10 | content | ACE-031: Reference Overview and Reconstitution Notes | section | Tools and supplies | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:section-12 | content | ACE-031: Reference Overview and Reconstitution Notes | section | What the research community gets wrong about ACE-031 (ramatercept) | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:product-bacteriostatic-water-30ml | products | ACE-031: Reference Overview and Reconstitution Notes | references product | Bacteriostatic Water 30 ml Multi-Dose Vial (Pfizer Hospira, USP) | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:product-gansulin-metal-peptide-pen | products | ACE-031: Reference Overview and Reconstitution Notes | references product | Gansulin Pen · Reusable Click-Dial, 3 ml (1-60 Units) | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:product-gansulin-3ml-cartridge | products | ACE-031: Reference Overview and Reconstitution Notes | references product | Gansulin-Compatible 3 ml Glass Cartridge for Pens (10-Pack) | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:product-complete-starter-kit | products | ACE-031: Reference Overview and Reconstitution Notes | references product | Complete Starter Kit — Pen, Cartridges & Bacteriostatic Water | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:source-pubmed-ncbi-nlm-nih-gov | source | ACE-031: Reference Overview and Reconstitution Notes | cites | Campbell et al., Muscle Nerve 2017: Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial - pubmed.ncbi.nlm.nih.gov | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:source-pubmed-ncbi-nlm-nih-gov-2 | source | ACE-031: Reference Overview and Reconstitution Notes | cites | Attie et al., Muscle Nerve 2013: A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers - pubmed.ncbi.nlm.nih.gov | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:source-pmc-ncbi-nlm-nih-gov | source | ACE-031: Reference Overview and Reconstitution Notes | cites | Cadena et al., PLoS One 2026: ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus) - pmc.ncbi.nlm.nih.gov | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:source-pmc-ncbi-nlm-nih-gov-2 | source | ACE-031: Reference Overview and Reconstitution Notes | cites | Reichel et al., Drug Test Anal 2025: Gel Electrophoretic Detection of Black Market ACE-031 - pmc.ncbi.nlm.nih.gov | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:source-www-uniprot-org | source | ACE-031: Reference Overview and Reconstitution Notes | cites | UniProtKB/Swiss-Prot Q13705: Activin receptor type-2B (ACVR2B, Homo sapiens), UniProt release 2026-03 - www.uniprot.org | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
| ace-031:source-clinicaltrials-gov | source | ACE-031: Reference Overview and Reconstitution Notes | cites | ClinicalTrials.gov NCT00952887 (Phase 1, completed, first posted 2009-08-06): A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women - clinicaltrials.gov | Lab article (https://www.preppinpeppers.com/blogs/the-lab/ace-031) (evidence) |
FAQ
- What is ACE-031 (ramatercept) and how does it work mechanistically?
- ACE-031 is a soluble ActRIIB-IgG1 fusion protein that acts as a ligand trap, sequestering myostatin and other TGF-beta superfamily ligands before they bind cell-surface receptors, thereby modulating muscle-growth signaling pathways.
- Why was ACE-031 clinical development discontinued?
- Trials were halted after participants experienced vascular side effects—nosebleeds, telangiectasias, and gum bleeding—attributed to off-target inhibition of BMP9, a protein required for blood vessel homeostasis.
- What is ACE-031's regulatory and WADA doping status?
- ACE-031 has no FDA approval or marketing authorization. It is prohibited at all times under WADA Prohibited List section S4.3, which covers myostatin inhibitors and activin receptor type II inhibitors.